Literature DB >> 6375858

Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13.

K S Webb, D F Paulson, S F Parks, F L Tuck, P J Walther, J L Ware.   

Abstract

The alpha-Pro 13-secreting hybridoma was produced by immunizing mice with an equal mixture of PC-3, DU145, and LNCaP established prostatic carcinoma cell lines. The specificity of alpha-Pro 13 monoclonal antibody was evaluated by the criteria of differential binding to cultured cells; differential binding to extracts of malignant prostate, nonmalignant prostate, and malignant and nonmalignant tissues of various histiotypes in solid phase radioimmunoassay; and by immunoperoxidase staining of primary surgical tissues of varied histiotypes. The data generated by multiple assay investigation indicate that alpha-Pro 13 exhibits preferential binding to the ductal epithelium of prostate tissue; immunoperoxidase evaluation indicates a considerable heterogeneity of staining of ductal epithelial cells. The most prevalent cross-reactivity of alpha-Pro 13 monoclonal antibody with non-prostate tissue occurs with blood vessel endothelium of restricted tissues. Electrophoretic analysis of immunoprecipitates from radioiodinated prostatic tumor extracts indicates that the molecule recognized by alpha-Pro 13 is of 120,000 dalton apparent nonreduced molecular weight. Under reducing conditions, the antigen (p40) consists of a major component of 40,000 dalton apparent MW and a minor component of 17,000 dalton MW. p40 has an isoelectric point of 3.5-4.5. The antigen is intrinsically stable on the PC-3 cell surface; its release into spent culture medium is negligible. p40 is also stable upon complexation with alpha-Pro 13 antibody in that it is not shed from the cell surface as an immune complex nor is it endocytosed to any extent as an immune complex.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375858     DOI: 10.1007/bf00205491

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Indirect 125I-labeled protein A assay for monoclonal antibodies to cell surface antigens.

Authors:  J P Brown; J D Tamerius; I Hellström
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

2.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

3.  Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.

Authors:  K S Webb; J L Ware; S F Parks; W H Briner; D F Paulson
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas.

Authors:  D Stramignoni; R Bowen; B F Atkinson; J Schlom
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

5.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

6.  Surface proteins of a transitional carcinoma cell line (KS-31E).

Authors:  K S Webb; K R Stone; Y Sharief; D F Paulson
Journal:  Urol Res       Date:  1980

7.  The LNCaP cell line--a new model for studies on human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg
Journal:  Prog Clin Biol Res       Date:  1980

8.  Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice.

Authors:  J L Ware; D F Paulson; G H Mickey; K S Webb
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

9.  Solubilization of yeast plasma membranes and mitochondria by different types of non-denaturing detergents.

Authors:  R Navarrete; R Serrano
Journal:  Biochim Biophys Acta       Date:  1983-03-09

10.  A serologic approach to the definition of human prostatic carcinoma antigens.

Authors:  K S Webb; J L Ware; S F Parks; D F Paulson
Journal:  Prostate       Date:  1981       Impact factor: 4.104

View more
  1 in total

1.  In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.

Authors:  K S Webb; S N Liberman; J L Ware; P J Walther
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.